|12.14|| +0.39 / +3.32%|
RedHill Biopharma Ltd. is a biopharmaceutical company that engages in the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. Its current pipeline of proprietary products includes: RHB-105, RHB-104, BEKINDA (RHB-102), RHB-106, YELIVA (ABC294640), MESUPRON, RP101, RIZAPORT (RHB-103), and RHB-101. RHB-105 is an oral combination therapy for the treatment of Helicobacter pylori infection. RHB-104 is an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study. BEKINDA (RHB-102) is a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis. RHB-106 is an encapsulated bowel preparation. YELIVA (ABC294640) is an orally-administered SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications with a Phase I/II study initiated for refractory/relapsed diffuse large B-cell lymphoma (DLBCL). MESUPRON is a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumors. RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers. RIZAPORT™ (RHB-103) is an oral thin film formulation of rizatriptan for acute migraines. RHB-101 is a once-daily oral pill formulation of the cardio drug carvedilol. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
|Dror Ben-Asher||Chairman & Chief Executive Officer|
|Ori Shilo||Deputy CEO- Finance & Operations|
|Micha Ben-Chorin||Chief Financial Officer|
|Reza Fathi||Senior Vice President-Research & Development|
|Clara Fehrmann||Director-Clinical Operations|